Added to YB: 2026-08-17
Pitch date: 2026-08-13
CPH.TO [neutral]
Cipher Pharmaceuticals Inc.
+1.65%
current return
Author Info
Company Info
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients.
Market Cap
CAD 327.5M
Pitch Price
CAD 13.91
Price Target
N/A
Dividend
N/A
EV/EBITDA
11.90
P/E
11.45
EV/Sales
6.42
Sector
Pharmaceuticals
Category
turnaround
Cipher Pharmaceuticals, Q2 2026 shares close -21.39%
CPH.TO (earnings): Q2 2026 shares -21%. Canadian specialty pharma ~2yrs post-ParaPro acquisition, shares languishing. Natroba (spinosad) for scabies/lice; differentiated MoA kills eggs, lowers resistance vs lotilaner. Bull: Walmart pharmacy stocking, OTC monograph upside. Bear: efficacy sandbagged by unlabeled benzyl alcohol in placebo trials; mgmt stalling on ex-US licensing seeking unrealistic prices for low-GDP endemic markets.
Read full article (3 min)